GotoPER - Physicians' Education Resource
Video

Module 8: Myelodysplastic Syndromes (MDS)

Create AccountAlready Registered? Login Here

Release Date

April 16, 2026

Expiration Date

March 1, 2027

Credits

1.25 CME, NCPD

Activity Overview

This educational activity is an archive of the live conference held from February 26, 2026, through February 28, 2026.

Target Audience 

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

Upon participation in this activity, learners will be better able to:

  • Evaluate recent clinical trial results on approved and emerging therapeutic approaches for patients with hematologic disorders
  • Interpret the latest guidelines and evidence for the use of biomarker-driven strategies to stratify risk and select appropriate therapies for patients with hematologic disorders
        Module 8: Myelodysplastic Syndromes (MDS)

        GET STARTED WITH THIS PROGRAM:

        Register now to gain access to this program.

        Create AccountAlready Registered? Login Here

        Click Here to return to Learning Hub

        Accreditation/Credit Designation

        Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

        Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

        Acknowledgment of Commercial Support

        This activity is supported by educational grants from Ascentage Pharma Inc; AstraZeneca Pharmaceuticals; Autolus Therapeutics; Daiichi Sankyo, Inc; Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals Corporation; PharmaEssentia; Rigel Pharmaceuticals, Inc; and Sanofi.

        Follow Us on Social Media!

        You Also Might Like...

        Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed PipelineVirtual Event

        Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

        Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare DisorderVirtual Event

        Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare Disorder

        Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential ThrombocythemiaVirtual Event

        Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

        Project ECHO®: A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and OutcomesVirtual Event

        Project ECHO®: A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

        Course

        Module 8: Myelodysplastic Syndromes (MDS)

        Create Account